MARCOS NAOYUKI SAMANO
Projetos de Pesquisa
Unidades Organizacionais
Departamento de Cardio-Pneumologia, Faculdade de Medicina - Docente
LIM/61 - Laboratório de Pesquisa em Cirurgia Torácica, Hospital das Clínicas, Faculdade de Medicina
LIM/61 - Laboratório de Pesquisa em Cirurgia Torácica, Hospital das Clínicas, Faculdade de Medicina
11 resultados
Resultados de Busca
Agora exibindo 1 - 10 de 11
- Lung transplantation: overall approach regarding its major aspects(2015) CAMARGO, Priscila Cilene Leon Bueno de; TEIXEIRA, Ricardo Henrique de Oliveira Braga; CARRARO, Rafael Medeiros; CAMPOS, Silvia Vidal; AFONSO JUNIOR, Jose Eduardo; COSTA, Andre Nathan; FERNANDES, Lucas Matos; ABDALLA, Luis Gustavo; SAMANO, Marcos Naoyuki; PEGO-FERNANDES, Paulo ManuelO transplante pulmonar é uma terapia bem estabelecida para pacientes com doença pulmonar avançada.A avaliação do candidato para o transplante é uma tarefa complexa e envolve uma equipe multidisciplinar que acompanha o paciente para além do período pós-operatório.O tempo médio atual em lista de espera para transplante pulmonar é de aproximadamente 18 meses no estado de São Paulo. Em 2014, dados da Associação Brasileira de Transplante de Órgãos mostram que 67 transplantes pulmonares foram realizados no Brasil e que 204 pacientes estavam na lista de espera para transplante pulmonar.O transplante pulmonar é principalmente indicado no tratamento de DPOC, fibrose cística, doença intersticial pulmonar, bronquiectasia não fibrocística e hipertensão pulmonar.Esta revisão abrangente teve como objetivos abordar os aspectos principais relacionados ao transplante pulmonar: indicações, contraindicações, avaliação do candidato ao transplante, avaliação do candidato doador, gestão do paciente transplantado e complicações maiores. Para atingirmos tais objetivos, utilizamos como base as diretrizes da Sociedade Internacional de Transplante de Coração e Pulmão e nos protocolos de nosso Grupo de Transplante Pulmonar localizado na cidade de São Paulo.
- Stents for Bronchial Stenosis After Lung Transplantation: Should They Be Removed?(2015) FONESCA, H. V. S.; IUAMOTO, L. R.; MINAMOTO, H.; ABDALLA, L. G.; FERNANDES, L. M.; CAMARGO, P. C. L.; SAMANO, M. N.; PEGO-FERNANDES, P. M.Background. Airway complications after lung transplantation are the major cause of morbidity, affecting up to 33% of all cases. Bronchial stenosis is the most common complication. The use of stents has been established as the most effective therapy; however, their removal is recommended after 3-6 months of use. We have been using self-expandable stents as a definitive treatment and remove them only if necessary. For this report, we evaluated the use of self-expandable stents as a definitive treatment for bronchial stenosis after lung transplantation. Methods. We performed a retrospective cohort study to evaluate patients with bronchial stenosis from August 2003 to April 2014. Clinical and pulmonary function test data were collected. Results. Two hundred lung transplants were performed, 156 of which were bilateral. Sixteen patients experienced airway complications: 4 had dehiscence, 2 necrosis, and 10 bronchial stenosis. Of these patients, 7 had undergone bilateral procedures, and 2 patients developed stenosis in both sides. Twelve anastomotic stenoses were observed. The follow-up after stenting ranged from 1 to 7 years. All patients had increased lung function, and 4 remained stable with sustained increase in pulmonary function without episodes of infection. Three patients required removal of their prosthesis 6 months to 1 year after implantation because of complications. Two patients died owing to unrelated causes. Conclusions. Definitive treatment of bronchial stenosis with self-expandable stents is a viable option. The 1st year seems to be the most crucial for determining definitive treatment, because no patients required removal of their stent after 1 year.
- Stents for Bronchial Stenosis After Lung Transplantation: Should They Be Removed? (vol 47, pg 1029, 2015)(2015) FONSECA, H. V. S.; IUAMOTO, L. R.; MINAMOTO, H.; ABDALLA, L. G.; FERNANDES, L. M.; CAMARGO, P. C. L.; SAMANO, M. N.; PEGO-FERNANDES, P. M.
conferenceObject INFLUENCE OF TREATMENT WITH HYPERTONIC SOLUTION BEFORE EVLP ON DONORS WITH HEMORRHAGIC SHOCK(2015) NEPOMUCENO, Natalia; OLIVEIRA-BRAGA, Karina Andrighetti; RUIZ, Liliane Moreira; CORREIA, Aristides Tadeu; SILVA, Eduardo Zinoni; PEGO-FERNANDES, Paulo Manuel; SAMANO, Marcos Naoyuki- Psychological criteria for contraindication in lung transplant candidates: 5 years survey(2015) COSTA, Andre Nathan; HOJAIJ, Elaine; ROMANO, Bellkis; CAMARGO, Priscila; CARRARO, Rafael; AFONSO JUNIOR, Jose Eduardo; CAMPOS, Silvia; MELLO, Liliane; SAMANO, Marcos; TEIXEIRA, Ricardo
- Building a Lung Transplant Program(2015) SAMANO, Marcos Naoyuki; PEGO-FERNANDES, Paulo Manuel
- Alternative solution for ex vivo lung perfusion, experimental study on donated human lungs non-accepted for transplantation(2015) FERNANDES, Lucas Matos; MARIANI, Alessandro Wasum; MEDEIROS, Israel Lopes de; SAMANO, Marcos Naoyuki; ABDALLA, Luís Gustavo; CORREIA, Aristides Tadeu; NEPOMUCENO, Natália Aparecida; CANZIAN, Mauro; PêGO-FERNANDES, Paulo ManuelPURPOSE: To evaluate a new perfusate solution to be used for ex vivo lung perfusion. METHODS: Randomized experimental study using lungs from rejected brain-dead donors harvested and submitted to 1 hour of ex vivo lung perfusion (EVLP) using mainstream solution or the alternative. RESULTS: From 16 lungs blocs tested, we found no difference on weight after EVLP: Steen group (SG) = 1,097±526g; Alternative Perfusion Solution (APS) = 743±248g, p=0.163. Edema formation, assessed by Wet/dry weigh ratio, was statistically higher on the Alternative Perfusion Solution group (APS = 3.63 ± 1.26; SG = 2.06 ± 0.28; p = 0.009). No difference on PaO2 after EVLP (SG = 498±37.53mmHg; APS = 521±55.43mmHg, p=0.348, nor on histological analyses: pulmonary injury score: SG = 4.38±1.51; APS = 4.50±1.77, p=0.881; apoptotic cells count after perfusion: SG = 2.4 ± 2.0 cells/mm2; APS = 4.8 ± 6.9 cells/mm2; p = 0.361). CONCLUSION: The ex vivo lung perfusion using the alternative perfusion solution showed no functional or histological differences, except for a higher edema formation, from the EVLP using Steen Solution(r) on lungs from rejected brain-dead donors.
- Can Patients Maintain Their Use of Everolimus Until Lung Transplantation?(2015) COSTA, Andre Nathan; BALDI, Bruno Guedes; TEIXEIRA, Ricardo Henrique de Oliveira Braga; SAMANO, Marcos Naoyuki; CARVALHO, Carlos Roberto Ribeiro de
- Psychological criteria for contraindication in lung transplant candidates: a five-year study(2015) HOJAIJ, Elaine Marques; ROMANO, Bellkiss Wilma; COSTA, André Nathan; AFONSO JUNIOR, Jose Eduardo; CAMARGO, Priscila Cilene Leon Bueno de; CARRARO, Rafael Medeiros; CAMPOS, Silvia Vidal; SAMANO, Marcos Naoyuki; TEIXEIRA, Ricardo Henrique de Oliveira BragaLung transplantation presents a wide range of challenges for multidisciplinary teams that manage the care of the recipients. Transplant teams should perform a thorough evaluation of transplant candidates, in order to ensure the best possible post-transplant outcomes. That is especially true for the psychologist, because psychological issues can arise at any point during the perioperative period. The objective of our study was to evaluate the psychological causes of contraindication to waiting list inclusion in a referral program for lung transplantation. We retrospectively analyzed data on psychological issues presented by lung transplant candidates, in order to understand these matters in our population and to reflect upon ways to improve the selection process.
conferenceObject THE EX VIVO RECONDITIONING EXPERIENCE IN BRAZIL(2015) OLIVEIRA-BRAGA, Karina Andrighetti; FERNANDES, Lucas Matos; ABADLLA, Luiz Gustavo; NEPOMUCENO, Natalia; SAMANO, Marcos Naoyuki; PEGO-FERNANDES, Paulo Manuel